Rebecca Gelman is involved in collaborative research on cancer and AIDS. She is coordinator of biostatistics collaboration at the Dana-Farber Cancer Institute, where she primarily works on breast cancer clinical trials, breast cancer screening studies, pathology studies, tumor marker studies, and immunogenetics. She is the coordinating statistician for the Harvard Collaborative Oncology Group, which involves cancer clinical trials and epidemiology studies at eight hospitals.
Her primary appointment is in the Radiation Oncology department of Harvard Medical School, where she works on breast cancer, prostate cancer and multiple myeloma studies. Dr. Gelman is section head for the Immunology Committee of the AIDS Clinical Trial Group, and serves on the Flow Advisory Committee of the NIAID. She works on clinical trials of immune-based therapies, runs the national program on flow cytometry quality assessment, and does research on the sources of variation and prognostic/surrog! ate value of immunology tests.
Dr. Gelman's statistical interests reflect her collaborative activities. She is currently involved in:
- proposing new methods for analysis of cancer screening trials,
- quantitating the value of quality assessment programs in prognostic and surrogate factor studies,
- comparing different methods of estimating confidence intervals for coefficient of variation, and
- developing competing risk models for long-term effects of chemotherapy and radiation.